Role of adenosine in diabetic retinopathy

Journal of Ocular Biology, Diseases, and Informatics

Volumn 4, Issue 1-2, 2011, Pages 19-24

  Liou, Gregory I ^a   Ahmad, Saif ^a   Naime, Mohammad ^a   Fatteh, Nadeem ^a   Ibrahim, Ahmed S ^b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

Adenosine; Adenosine receptors; Cannabinoids; Diabetic retinopathy; Microglia

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CYCLIC AMP; DIPYRIDAMOLE; DRONABINOL; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; INTERCELLULAR ADHESION MOLECULE 1; MITOGEN ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ARTHRITIS; BLINDNESS; BRAIN INFARCTION; BRAIN ISCHEMIA; CELL ACTIVATION; CYTOKINE RELEASE; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; GLAUCOMA; HUMAN; MICROGLIA; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA NEOVASCULARIZATION; RETINITIS; REVIEW; UVEITIS;

EID: 84863984005     PISSN: 19368437     EISSN: 19368445     Source Type: Journal    
DOI: 10.1007/s12177-011-9067-5     Document Type: Review

References (68)

1. Klein R, et al. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1984;102 (4):520-6. (Pubitemid 14127838)
2. Rungger-Brandle E, Dosso AA, Leuenberger PM. Glial reactivity, an early feature of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2000;41(7):1971-80. (Pubitemid 30354375)
3. Zeng XX, Ng YK, Ling EA. Neuronal and microglial response in the retina of streptozotocin-induced diabetic rats. Vis Neurosci. 2000;17(3):463-71.
4. Ammary-Risch NJ, Huang SS. The primary care physician's role in preventing vision loss and blindness in patients with diabetes. J Natl Med Assoc. 2011;103(3):281-3.
5. Cogan DG, Toussaint D, Kuwabara T. Retinal vascular patterns. IV. Diabetic retinopathy. Arch Ophthalmol. 1961;66:366-78.
6. Bursell SE, et al. Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy. Invest Ophthalmol Vis Sci. 1996;37(5):886-97.
7. Benson WE, et al. Current popularity of pneumatic retinopexy. Retina. 1999;19(3):238-41. (Pubitemid 30368140)
8. Palmberg PF. Diabetic retinopathy. Diabetes. 1977;26(7):703-9. (Pubitemid 8149659)
9. Joussen AM, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18(12):1450-2. (Pubitemid 39561611)
10. Barber AJ, et al. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest. 1998;102(4):783-91. (Pubitemid 28399611)
11. El-Remessy AB, et al. Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor. Am J Pathol. 2003;162(6):1995-2004. (Pubitemid 36613056)
12. El-Remessy AB, et al. Neuroprotective and blood-retinal barrierpreserving effects of cannabidiol in experimental diabetes. Am J Pathol. 2006;168(1):235-44. (Pubitemid 43062576)
13. Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res. 2007;2007:95103.
14. Ali TK, et al. Peroxynitrite mediates retinal neurodegeneration by inhibiting nerve growth factor survival signaling in experimental and human diabetes. Diabetes. 2008;57(4):889-98.
15. Langmann T. Microglia activation in retinal degeneration. J Leukoc Biol. 2007;81(6):1345-51. (Pubitemid 46827958)
16. Lieth E, et al. Diabetes reduces glutamate oxidation and glutamine synthesis in the retina. The Penn State Retina Research Group. Exp Eye Res. 2000;70(6):723-30.
17. El-Remessy AB, et al. Cannabidiol protects retinal neurons by preserving glutamine synthetase activity in diabetes. Mol Vis. 2010;16:1487-95.
18. Ambati J, et al. Elevated gamma-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol. 1997;115(9):1161-6. (Pubitemid 27387953)
19. Lieth E, et al. Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Penn State Retina Research Group. Diabetes. 1998;47(5):815-20. (Pubitemid 28201813)
20. Kowluru RA, et al. Retinal glutamate in diabetes and effect of antioxidants. Neurochem Int. 2001;38(5):385-90. (Pubitemid 32166895)
21. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 1993;262(5134):689-95. (Pubitemid 23350687)
22. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996;19(8):312-8. (Pubitemid 26349059)
23. Madsen-Bouterse SA, Kowluru RA. Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Rev Endocr Metab Disord. 2008;9(4):315-27.
24. Aloisi F. Immune function of microglia. Glia. 2001;36(2):165-79. (Pubitemid 33055905)
25. Wood PL. Neuroinflammation: mechanisms and management. Totowa New York, NY: Humana Press; 2003.
26. Zeng HY, Green WR, Tso MO. Microglial activation in human diabetic retinopathy. Arch Ophthalmol. 2008;126(2):227-32. (Pubitemid 351240852)
27. Yang LP, et al. Baicalein reduces inflammatory process in a rodent model of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2009;50 (5):2319-27.
28. Liu W, et al. Expression of macrophage colony-stimulating factor (M-CSF) and its receptor in streptozotocin-induced diabetic rats. Curr Eye Res. 2009;34(2):123-33.
29. Ibrahim AS, et al. Genistein attenuates retinal inflammation associated with diabetes by targeting of microglial activation. Mol Vis. 2010;16:2033-42.
30. Joussen AM, et al. TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and longterm histopathological alterations. Mol Vis. 2009;15:1418-28.
31. Joussen AM, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J. 2002;16(3):438-40.
32. Krady JK, et al. Minocycline reduces proinflammatory cytokine expression,microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes. 2005. doi:10.2337/db54.5.1559.
33. Ibrahim AS, et al. Retinal microglial activation and inflammation induced by amadori-glycated albumin in a rat model of diabetes. Diabetes. 2011;60(4):1122-33.
34. Schalkwijk CG, et al. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia. 1999;42(3):351-7. (Pubitemid 29111443)
35. Tang J, et al. Retina accumulates more glucose than does the embryologically similar cerebral cortex in diabetic rats. Diabetologia. 2000;43(11):1417-23.
36. Wang AL, et al. AGEs mediated expression and secretion of TNF alpha in rat retinal microglia. Exp Eye Res. 2007;84(5):905-13. (Pubitemid 46613882)
37. Schalkwijk CG. Comment on "AGEs mediated expression and secretion of TNF alpha in rat retinal microglia" by Dr Wang et al. Exp Eye Res. 2007;85:572-3. doi:4. author reply 574. (Pubitemid 47534205)
38. Quan Y, Du J, Wang X. High glucose stimulates GRO secretion from rat microglia via ROS, PKC, and NF-kappaB pathways. J Neurosci Res. 2007;85(14):3150-9. (Pubitemid 350057371)
39. Collis MG, Hourani SM. Adenosine receptor subtypes. Trends Pharmacol Sci. 1993;14(10):360-6. (Pubitemid 23308759)
40. Fredholm BB, et al. Nomenclature and classification of purinoceptors. Pharmacol Rev. 1994;46(2):143-56. (Pubitemid 24984777)
41. Feoktistov I, Goldstein AE, Biaggioni I. Role of p38 mitogenactivated protein kinase and extracellular signal-regulated protein kinase kinase in adenosine A2B receptor-mediated interleukin-8 production in human mast cells. Mol Pharmacol. 1999;55(4):726-34. (Pubitemid 29165438)
42. Bong GW, Rosengren S, Firestein GS. Spinal cord adenosine receptor stimulation in rats inhibits peripheral neutrophil accumulation. The role of N-methyl-D-aspartate receptors. J Clin Invest. 1996;98(12):2779-85.
43. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev. 1998;50(3):413-92. (Pubitemid 28477681)
44. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature. 2001;414(6866):916-20. (Pubitemid 34024743)
45. Awad AS, et al. Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy. Am J Physiol Renal Physiol. 2006;290(4):F828-37. (Pubitemid 43724943)
46. Liou GI, et al. Mediation of cannabidiol anti-inflammation in the retina by equilibrative nucleoside transporter and A2A adenosine receptor. Invest Ophthalmol Vis Sci. 2008;49(12):5526-31.
47. Ibrahim AS, et al. A(2A) adenosine receptor (A(2A)AR) as a therapeutic target in diabetic retinopathy. Am J Pathol. 2011;178 (5):2136-45.
48. Williams M. Challenges in developing P2 purinoceptor-based therapeutics. CIBA Found Symp. 1996;198:309-21. (Pubitemid 126793195)
49. Moser GH, Schrader J, Deussen A. Turnover of adenosine in plasma of human and dog blood. Am J Physiol. 1989;256(4 Pt 1):C799-806.
50. Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA. 2006;103(20):7895-900.
51. Dunwiddie TV, Diao L. Regulation of extracellular adenosine in rat hippocampal slices is temperature dependent: role of adenosine transporters. Neuroscience. 2000;95(1):81-8.
52. Picano E, Michelassi C. Chronic oral dipyridamole as a 'novel' antianginal drug: the collateral hypothesis. Cardiovasc Res. 1997;33(3):666-70. (Pubitemid 27092868)
53. De Schryver EL. Dipyridamole in stroke prevention: effect of dipyridamole on blood pressure. Stroke. 2003;34(10):2339-42. (Pubitemid 37221937)
54. De la Cruz JP, et al. Effect of aspirin plus dipyridamole on the retinal vascular pattern in experimental diabetes mellitus. J Pharmacol Exp Ther. 1997;280(1):454-9. (Pubitemid 27171434)
55. Leung GP, Man RY, Tse CM. D-Glucose upregulates adenosine transport in cultured human aortic smooth muscle cells. Am J Physiol Heart Circ Physiol. 2005;288(6):H2756-62. (Pubitemid 40720655)
56. Pawelczyk T, Podgorska M, Sakowicz M. The effect of insulin on expression level of nucleoside transporters in diabetic rats. Mol Pharmacol. 2003;63(1):81-8. (Pubitemid 36043811)
57. Buckley NE, et al. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol. 2000;396(2-3):141-9. (Pubitemid 30265571)
58. Crandall J, et al. Neuroprotective and intraocular pressurelowering effects of (-)Delta9-tetrahydrocannabinol in a rat model of glaucoma. Ophthalmic Res. 2007;39(2):69-75. (Pubitemid 46909862)
59. Mechoulam R, Parker LA, Gallily R. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol. 2002;42(11 Suppl):11S-9S. (Pubitemid 35205041)
60. Hampson AJ, et al. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA. 1998;95(14):8268-73. (Pubitemid 28326102)
61. Malfait AM, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collageninduced arthritis. Proc Natl Acad Sci USA. 2000;97(17):9561-6. (Pubitemid 30650815)
62. El-Remessy AB, et al. Neuroprotective effects of cannabidiol in endotoxin-induced uveitis: critical role of p38 MAPK activation. Mol Vis. 2008;14:2190-203.
63. Braida D, et al. Post-ischemic treatment with cannabidiol prevents electroencephalographic flattening, hyperlocomotion and neuronal injury in gerbils. Neurosci Lett. 2003;346(1-2):61-4. (Pubitemid 36792194)
64. Mishima K, et al. Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism. Stroke. 2005;36(5):1077-82.
65. Rajesh M, et al. Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am J Physiol Heart Circ Physiol. 2007;293(1):H610-9. (Pubitemid 47105122)
66. Weiss L, et al. Cannabidiol lowers incidence of diabetes in nonobese diabetic mice. Autoimmunity. 2006;39(2):143-51. (Pubitemid 43675258)
67. Barnes MP. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin Pharmacother. 2006;7(5):607-15.
68. Liou G, et al. Cannabidiol as a putative novel therapy for diabetic retinopathy: a postulated mechanism of action as an entry point for biomarker-guided clinical development. Curr Pharmacogenomics Person Med. 2009;7(3):215-22.